Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MF-766 是高效的、具有口服活性的EP4选择性拮抗剂,Ki 为 0.23 nM。它在功能检测中表现为一种完整的拮抗剂,其 IC50为 1.4 nM (在 10% HS 存在时变成 1.8 nM)。它具有用于癌症和炎症疾病研究的价值。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 723 | 现货 | ||
5 mg | ¥ 1,820 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,850 | 现货 | ||
50 mg | ¥ 6,890 | 现货 | ||
100 mg | ¥ 9,330 | 现货 | ||
500 mg | ¥ 18,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,860 | 现货 |
产品描述 | MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research[1][2]. |
靶点活性 | EP4:0.23 nM (Ki) |
体外活性 | MF-766 (0.01-10 μM; pretreatment for 1 h and then stimulated with 50 ng/mL IL-2; with and without 0.33 μM PGE2; 18 hours) reverses PGE2-suppressed IFN-γ secretion in human NK cells. Moreover, NK cell viability is not affected by MF-766[2]. |
体内活性 |
MF-766 (oral gavage; 30 mg/kg; once daily; 21 days) exhibits TGI% of 49% in CT26 tumor model. But it does not exhibits significant difference in EMT6 and 4T1 tumor model[2]. MF-766 (oral gavage; 30 mg/kg combination with anti-PD-1 mDX400; once daily; 21 days; q4dx8) shows potent anti-tumor activities in different preclinical models. The % of TGI are 89%, 66% and 40%, respectively in CT26 tumor, EMT6 and 4T1 tumor model[2]. |
分子量 | 478.46 |
分子式 | C27H21F3N2O3 |
CAS No. | 1050656-06-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.50 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.09 mL | 10.4502 mL | 20.9004 mL | 52.251 mL |
5 mM | 0.418 mL | 2.09 mL | 4.1801 mL | 10.4502 mL | |
10 mM | 0.209 mL | 1.045 mL | 2.09 mL | 5.2251 mL | |
20 mM | 0.1045 mL | 0.5225 mL | 1.045 mL | 2.6125 mL | |
50 mM | 0.0418 mL | 0.209 mL | 0.418 mL | 1.045 mL | |
100 mM | 0.0209 mL | 0.1045 mL | 0.209 mL | 0.5225 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MF-766 1050656-06-8 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor EP4 arthritis inflammation disease AIA inhibit anti-tumor MF766 MF 766 Inhibitor cancer inhibitor